As of Nov 19, 2026, 1 of 1 active firms rate INKT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
INKT EPS & revenue forecast
EPS · NEXT QUARTER
—
Range — – — · 0 analysts
Next period, 0 analysts expect Mink Therapeutics Inc to earn — a share (range — – —), versus — a year earlier. Full-year consensus is $-2.45, growing to $-0.72 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 0 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Mink Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on INKT.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$43.00+381.8% to target
Overall win rate
49%
+ Follow
#2
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$35.00+292.2% to target
Overall win rate
24%
+ Follow
#3
MP
Matt Phipps
William Blair
Neutral
No targeton INKT
Coverage
—
+ Follow
INKT stock forecast FAQ
What is INKT's average 12-month price target?+
The 1 active firms with a live target average $35.00 for Mink Therapeutics Inc over the next 12 months, ranging from a $35.00 high to a $35.00 low, as of Nov 19, 2026.
Is INKT stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover INKT?+
1 active firms have a recognized rating on Mink Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering INKT?+
Among analysts who currently cover INKT, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $43.00 target.
What is Mink Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is — per share (range — – —) across 0 analysts. Full-year EPS is projected at $-2.45, rising to $-0.72 the following year.
How much revenue is Mink Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading INKT lately?+
As of Nov 19, 2026, 1 of 1 active firms rate INKT a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their INKT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.